SEP 2014 ARTICLE LIST >>
PharmaTutor (September- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 9)
Received On: 02/07/2014; Accepted On: 08/07/2014; Published On: 01/09/2014
AUTHORS: Palak G. Chaudhary1*, Bhavini N. Patel1, Chhagan N. Patel2
1Department of Quality Assurance,
2Department of Pharmaceutical Chemistry
Shri Sarvajanik Pharmacy College, Mehsana, Gujarat, India.
*palakc24@gmail.com
ABSTRACT:
High performance liquid chromatographic method was developed and validated for the determination of Darunavir Ethanolate in tablet dosage form. The method was carried out on a Phenomenex luna C18 Column (150 × 4.6 mm id, 5µ) maintained at 30oC. The mobile phase consisted of water-acetonitrile (60 + 40, v/v) pumped at a flow rate 1.0 mL/min. Photo diode array detection was at 265 nm. The chromatographic separation was obtained with a retention time of 11.8 min, and the method was linear in the range of 1-30 µg/mL (r2 = 0.9997). The specificity and stability indicating capability of the method was proven through forced degradation studies, which also showed that there was no interference of the excipients. The method was validated for linearity, precision, accuracy, robustness, specificity, limit of detection and limit of quantitation. The developed method, after being validated was successively applied to the analysis of tablet formulations. The drug could be effectively separated from different degradation products and hence the method can be used for stability analysis.
How to cite this article: PG Chaudhary, BN Patel, CN Patel; A validated Stability-indicating High Performance Liquid Chromatographic Method for Darunavir Ethanolate in Tablet Dosage Form; PharmaTutor; 2014; 2(9); 91-100
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. Antmicrob Agents Chemother, 2003;47(10):3123-3129.
2.De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antmicrob Agents Chemother, 2005;49(6):2314-2321.
3.Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, et at. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol, 2004;338(2):341-352.
4.King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol, 2004;78(41):12012-12021.
5.Patel BN, Suhagia BN, Patel CN. RP-HPLC method development and validation for estimation of Darunavir ethanolate in tablet dosage form. International Journal of pharmacy & pharmaceutical science, 2012;4(3):270-273.
6.Goldwirt L, Chhun S, Rey E, Launay O, Viard JP, Pons G, et al. Quantification of Darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violate detection. J Chromatography B, 2007;857(2):327-331.
7.Patel BN, Suhagia BN, Patel CN, Panchal HJ. A simple and sensitive HPTLC method for quantitative analysis of Darunavir ethanolate tablets. Journal Planer Chromatography, 2011;24(3):232-235.
8.Rezk NL, White NR, Jennings SH, Angela DM. A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. Talanta, 2009;79(5):1372-1378.
9.D’Avolio A, Siccardi M, Sciandra M, Baietto L, Bonora S, Trentini L, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatography B, 2007;859(2):234–240.
10.Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et at. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. J Chromatography B, 2009;877(11-12):1057-1069.
11.Takahashi M, Kudaka Y, Okumura N, Hirano A, Banno K, Kaneda T. The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors. Bio Pharm Bull, 2007;30(10):1947-1949.
12.Singh S, Singh B, Bahuguna R, Wadhwa L, Saxena R. Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay. J Pharm Biomed Anal, 2006;41(3):1037-1040.
13. ICH Q1A (R2), Stability Testing of New Drugs Substance and Products. Geneva: International Conference on Harmonization; 2003. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qua.... [Last accessed on 2014 June 09].
14. Ivana I, Ljiljana Z, Mira Z. A stability indicating assay method for cefuroxime axetil and its application to analysis of tablets exposed to accelerated stability test conditions. J Chromatography B, 2006;1119(1-2):209-215.
15. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology. Geneva: International Conference on Harmonization; 2005. Available from: ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qua.... [Last accessed on 2014 June 09].
.png)
